Literature DB >> 9102222

The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector.

F Tanaka1, M Abe, T Akiyoshi, T Nomura, K Sugimachi, T Kishimoto, T Suzuki, M Okada.   

Abstract

Interleukin-6 (IL-6) was found to function as a late-acting killer helper factor in the differentiation of CTLs. In the model of tumor-bearing mice, the systemic administration of recombinant IL-6 was found to mediate the antitumor effect on the immunogenic murine tumors via the in vivo induction of murine CTLs but not on the poorly immunogenic murine tumors in our previous study. However, an in vivo experimental model capable of analyzing the anti-human tumor effect via the in vivo induction of human CTLs has not yet been established. Therefore, in the present study, severe combined immunodeficient mice were given human peripheral blood lymphocytes (SCID-PBL/hu), and thereafter human tumor cells were administered i.p. into these SCID-PBL/hu mice as a model of human patients with cancer. When these SCID-PBL/hu mice bearing allogeneic human CESS B blastoid tumor cells were treated in vivo with recombinant adenovirus vector expressing IL-6 cDNA, both the induction of CD8+ human CTLs against CESS cells in the spleen cells and peritoneal exudate cells and a prolongation in the survival of these mice were observed. Furthermore, SCID-PBL/hu mice were given peripheral blood lymphocytes from patients with cancer (gastric or rectal cancers) and autologous human tumor cells. The in vivo administration of recombinant adenovirus vector expressing IL-6 cDNA induced CD8+ human CTLs specific for autologous human tumor cells from human precursor T cells. The in vivo injection of the IL-6 gene also inhibited growth and metastasis in autologous human cancers. Based on the above findings, the experimental model using SCID-PBL/hu mice and the IL-6 gene delivered in vivo by an adenovirus vector might therefore provide a new strategy capable of analyzing an anti-human tumor effect and the in vivo induction of human CTLs by cytokine gene therapy without using the human body.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9102222

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  The study of novel DNA vaccines against tuberculosis: induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Toshihiro Nakajima; Satomi Hashimoto; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

2.  Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models.

Authors:  Masaji Okada; Yuji Takemoto; Yoshinobu Okuno; Satomi Hashimoto; Yukari Fukunaga; Takao Tanaka; Yoko Kita; Sechiko Kuwayama; Yumiko Muraki; Noriko Kanamaru; Hiroko Takai; Chika Okada; Yayoi Sakaguchi; Izumi Furukawa; Kyoko Yamada; Miwa Izumiya; Shigeto Yoshida; Makoto Matsumoto; Tetsuo Kase; J S M Peiris; Daphne E DeMello; Pei-Jer Chen; Naoki Yamamoto; Yoshiyuki Yoshinaka; Tatsuji Nomura; Isao Ishida; Shigeru Morikawa; Masato Tashiro; Mitsunori Sakatani
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

3.  Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice.

Authors:  Masaji Okada; Yoko Kita; Noriko Kanamaru; Satomi Hashimoto; Yasushi Uchiyama; Masahiko Mihara; Yoshikazu Inoue; Yoshiyuki Ohsugi; Tadamitsu Kishimoto; Mitsunori Sakatani
Journal:  Clin Dev Immunol       Date:  2011-02-22

4.  Novel therapeutic vaccines [(HSP65 + IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy.

Authors:  Yoko Kita; Satomi Hashimoto; Toshihiro Nakajima; Hitoshi Nakatani; Shiho Nishimatsu; Yasuko Nishida; Noriko Kanamaru; Yasuhumi Kaneda; Yasushi Takamori; David McMurray; Esterlina V Tan; Marjorie L Cang; Paul Saunderson; E C Dela Cruz; Masaji Okada
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

5.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

6.  Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis.

Authors:  Masaji Okada; Yoko Kita; Toshihiro Nakajima; Noriko Kanamaru; Satomi Hashimoto; Tetsuji Nagasawa; Yasufumi Kaneda; Shigeto Yoshida; Yasuko Nishida; Hitoshi Nakatani; Kyoko Takao; Chie Kishigami; Shiho Nishimatsu; Yuki Sekine; Yoshikazu Inoue; David N McMurray; Mitsunori Sakatani
Journal:  Clin Dev Immunol       Date:  2011-03-07

7.  Clinical significance of immune cell infiltration within gallbladder cancer.

Authors:  Y Nakakubo; M Miyamoto; Y Cho; Y Hida; T Oshikiri; M Suzuoki; K Hiraoka; T Itoh; S Kondo; H Katoh
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

8.  Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.

Authors:  P Osterlund; A Orpana; I Elomaa; H Repo; H Joensuu
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

Review 9.  Mouse models with human immunity and their application in biomedical research.

Authors:  Baojun Zhang; Ziyuan Duan; Yong Zhao
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

10.  Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models.

Authors:  Masaji Okada; Yoshinobu Okuno; Satomi Hashimoto; Yoko Kita; Noriko Kanamaru; Yasuko Nishida; Yoshie Tsunai; Ruriko Inoue; Hitoshi Nakatani; Reiko Fukamizu; Yumi Namie; Junko Yamada; Kyoko Takao; Ritsuko Asai; Ryoko Asaki; Tetsuo Kase; Yuji Takemoto; Shigeto Yoshida; J S M Peiris; Pei-Jer Chen; Naoki Yamamoto; Tatsuji Nomura; Isao Ishida; Shigeru Morikawa; Masato Tashiro; Mitsunori Sakatani
Journal:  Vaccine       Date:  2007-01-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.